Epithelial ovarian cancer (EOC) is a deadly cancer, and its prognosis has not been changed significantly during several decades. To seek new therapeutic targets for EOC, we performed an in vivo dropout screen in human tumor xenografts using a pooled shRNA library targeting thousands of druggable genes. Then, in follow-up studies, we performed a second screen using a genome-wide CRISPR/Cas9 library. These screens identified 10 high-confidence drug targets that included well-known oncogenes such as ERBB2 and RAF1, and novel oncogenes, notably KPNB1, which we investigated further. Genetic and pharmacological inhibition showed that KPNB1 exerts its antitumor effects through multiphase cell cycle arrest and apoptosis induction. Mechanistically, proteomic studies revealed that KPNB1 acts as a master regulator of cell cycle-related proteins, including p21, p27, and APC/ C. Clinically, EOC patients with higher expression levels of KPNB1 showed earlier recurrence and worse prognosis than those with lower expression levels of KPNB1. Interestingly, ivermectin, a Food and Drug Administration-approved antiparasitic drug, showed KPNB1-dependent antitumor effects on EOC, serving as an alternative therapeutic toward EOC patients through drug repositioning. Last, we found that the combination of ivermectin and paclitaxel produces a stronger antitumor effect on EOC both in vitro and in vivo than either drug alone. Our studies have thus identified a combinatorial therapy for EOC, in addition to a plethora of potential drug targets.
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ovarian cancer | KPNB1 | loss-of-function screen | CRISPR/Cas | RNAi E pithelial ovarian cancer (EOC) is the fifth leading cause of cancer-related deaths among women in the United States and the most lethal gynecological cancer (1) . Because of its rapid growth and lack of effective early detection strategies, 70% of EOC patients are diagnosed at an advanced stage, accompanied by peritoneal carcinomatosis (PC) (2) . Most EOC patients also eventually become refractory to platinum, the major drug for treating EOC (3) . Importantly, there are few molecularly targeted agents available for treating EOC, likely because EOC has high intertumor and intratumor heterogeneity at the molecular and epigenetic levels (4) . Therefore, the mortality rate of EOC has not been significantly changed for several decades (5) . To improve the poor prognosis of EOC, the discovery of new drug targets is sorely needed.
To elucidate the molecular pathogenesis of EOC, the Cancer Genome Atlas project has performed whole-genome sequencing and DNA copy number analysis of 489 patients with high-grade serous ovarian cancer, the most common type of cancer found in EOC patients. Sequencing revealed that almost all tumors (96%) had mutations in TP53, which serves as a major driver of this cancer (6) . Low-prevalence but statistically significant mutations in nine other genes including NF1, BRCA1, BRCA2, RB1, and CDK12 were also identified, but the majority of genes were mutated at low frequency, making it difficult to distinguish between driver and passenger mutations.
To overcome this problem, several alternative methods have recently been used for cancer gene discovery, including insertional mutagenesis and RNAi/shRNA/CRISPR/Cas9-based screens. In our laboratory, we have performed transposon-based mutagenesis screens for a variety of cancer types and successfully identified many candidate cancer genes in a high-throughput manner (7, 8) . However, the lack of EOC mouse models that recapitulate human EOC has hampered our use of this technology for cancer gene discovery in EOC. Although several groups have used pooled RNAi library screens for identifying new drug targets for EOC, most of these screens were performed in vitro (9, 10), which may not represent the clinical setting. To overcome these limitations, we performed an in vivo loss-of-function screen in human tumor xenografts using a pooled shRNA library targeting thousands of druggable genes. Then, in follow-up studies, we performed a second screen using a genomewide CRISPR/Cas9 library. These screens identified 10 high-confidence candidate drug targets for EOC. In addition, we functionally validated a potent EOC oncogene, KPNB1, and showed its clinical relevance to human EOC. We also showed that a well-established
Significance
The poor prognosis of epithelial ovarian cancer (EOC) has not improved for several decades because of drug resistance to current anticancer drugs. Furthermore, few molecularly targeted agents are effective for EOC, likely because EOC has high tumor heterogeneity. Discovering new drug targets and mechanisms involved in the progression of EOC is therefore sorely needed. Our multiple CRISPR and RNAi-based in vivo loss-of-function screens have identified multiple new EOC candidate drug targets, including the druggable oncogene KPNB1, whose inhibition caused multiphased cell cycle arrest and induced apoptosis. Ivermectin, a Food and Drug Administration-approved antiparasitic drug, exerts KPNB1-dependent antitumor effects and synergistically inhibits tumor growth in combination with paclitaxel, and therefore represents a new potential combinatorial therapy for EOC through drug repositioning.
antiparasitic drug, ivermectin, has antitumor effects on EOC through its inhibition of KPNB1, and describe a combinational therapy for treating EOC.
Results
An in Vivo Loss-of-Function Screen Identifies Potent Drug Targets for EOC. To identify new drug targets for EOC, we conducted an in vivo dropout screen using a pooled shRNA library targeting 7,490 druggable genes (Fig. 1A) . We performed this screen using an established EOC PC model (11) , since PC is the biggest contributing factor to the lethality of EOC. In this screen, the human serous ovarian cancer cell line, SKOV3, was lentivirally transduced with the shRNA library and then i.p. injected into female nude mice. Genomic DNA from the PC tumors was PCR-amplified and sequenced to identify shRNAs depleted in tumors compared with transduced cells (Fig. 1A and Dataset S1). By focusing on depleted shRNAs, we hoped to identify drug targets whose inhibition would efficiently suppress PC formation. Thousands of shRNAs were depleted in tumors through in vivo selective pressure (Fig. 1B) . The top 10 genes, which had multiple shRNAs showing substantial depletion in PC tumors, are shown in Fig. 1C (see Methods for detailed criteria). To confirm the validity of these results, we repeated the screen and confirmed that most of the shRNAs targeting the top 10 genes were consistently depleted in tumors (Fig. 1C) , excluding the possibility that this depletion was due to random chance.
We conducted another screen using a genome-scale CRISPR/ Cas9 knockout library (GeCKOv2) (12) . Interestingly, most of the single-guide RNAs (sgRNAs) targeting the top 10 genes identified in our initial shRNA library screen were also depleted in the CRISPR screen ( Fig. S1 and Dataset S1), further confirming that these genes are essential for PC tumors to survive. Among the top 10 genes, ERBB2 and RAF1 are well-known oncogenes in many solid tumors (13, 14) and several HER2 inhibitors have already been used in the clinic for multiple cancer types (15) , confirming that our screen is capable of identifying promising drug targets.
To verify the potential of these genes as drug targets, we assessed the effect of their depletion on cell proliferation/survival, which is highly related to tumor growth (16) . In agreement with the results of our in vivo screen, individual knockdown of all but one gene decreased cell proliferation/survival (Fig. S2) . Taken together, these results suggest that our screen provides a good resource to identify potential drug targets for EOC. KPNB1 Is a Drug Target Candidate for EOC. Since Food and Drug Administration (FDA)-approved drugs are already in clinical use for our top-ranked gene ERBB2, we decided to test the potential of our second-ranked gene, KPNB1 (karyopherin beta-1 or, alternatively, importin beta-1), as a new drug target for EOC. First, to validate our initial screening results, we individually transduced KPNB1 shRNAs or negative control (NC) shRNA into SKOV3 cells and then i.p. injected them into nude mice. KPNB1 knockdown by any of the three shRNAs (Fig. S3A ) significantly reduced tumor size and numbers in their peritoneal cavity ( Fig. 2A) . We also assessed the effect of KPNB1 knockdown on cell proliferation/ survival in three human EOC cell lines, SKOV3, CAOV3, and OVCAR3. The siRNA-mediated knockdown of KPNB1 (Fig. S3 B-D) significantly decreased cell proliferation/survival in all three lines (Fig. 2 B-D) . We then examined the antitumor effect of pharmacological inhibition of KPNB1 using importazole, a small molecule that specifically inhibits the importin β family (17) . Consistent with our siRNA results, blockade of KPNB1 by importazole also significantly reduced cell proliferation/survival in a dosedependent manner (Fig. 2E) . Collectively, these results identify KPNB1 as a promising therapeutic target for EOC.
KPNB1 Inhibition Induces Apoptosis. To investigate the mechanism of the antitumor effect resulting from KPNB1 inhibition, we first focused on apoptotic cell death, which is one of the major determinants of cell proliferation/survival. KPNB1 inhibition via any of three KPNB1 siRNAs or importazole treatment induced apoptosis in human EOC cell lines ( Fig. 3 A-F and Fig. S4 ), and was accompanied by an increase in the expression levels of the proapoptotic proteins BAX and cleaved caspase-3 ( Fig. 3G) . Furthermore, immunohistochemical staining showed an increase in the number of cleaved PARP-positive tumor cells in tissue sections (18) from xenografted tumors containing KPNB1 shRNAs (Fig. 3H) , further confirming that KPNB1 inhibition induces apoptosis both in vitro and in vivo, and providing a mechanism for its antitumor effect in EOC.
KPNB1 Inhibition Induces Multiphase Cell Cycle Arrest. We next examined the effect of KPNB1 inhibition on the cell cycle, another strong determinant of cell proliferation/survival. Knockdown of KPNB1 elevated the population of cells at the G2/M phase as measured by flow cytometric analysis ( Fig. 4 A and B) . To assess each stage of the cell cycle individually, we treated cells with nocodazole, an inhibitor of microtubule polymerization (19) , to induce mitotic arrest. Twenty-four hours later, while the majority of the cells treated with NC siRNA were accumulated at the G2/ M phase, a large fraction of cells treated with KPNB1 siRNAs still remained at the G1/S phase ( Fig. 4 A and B) , suggesting that KPNB1 inhibition delays the G1/S transition. In addition, 24 h after the withdrawal of nocodazole, the G2/M population in KPNB1 knockdown cells further increased, in sharp contrast to the rapid decrease of the G2/M population in control cells (Fig. 4 A and B), further suggesting that KPNB1 inhibition also delays the G2/M transition. We also confirmed that pharmacological inhibition of KPNB1 by importazole produced a similar effect ( Fig. 4 C and D) . We then checked the expression levels of a number of cell cycle regulators and found that KPNB1 inhibition increased p21 and p27 protein levels ( Fig. 4E and Fig. S5 ). We also assessed the cell cycle in xenografted tumors derived from SKOV3 cells transduced with KPNB1 shRNAs. Immunohistochemical staining showed that the number of Ki67 positive cells was significantly lower in tumors transduced with KPNB1 shRNA (Fig. 4F ), suggesting that KPNB1 inhibition also delayed cell cycle progression in vivo. Taken together, these results suggest that KPNB1 inhibition exerts its antitumor effect, in part, by inducing apoptosis and cell cycle arrest in human EOC.
KPNB1 Functions as an Oncogene in EOC.
These results prompted us to examine whether KPNB1 acts as an oncogene in EOC. Stable overexpression of KPNB1 in SKOV3 and OVCAR3 (Fig. S6 ) significantly accelerated cell proliferation/survival (Fig. 5 A-C) , confirming that KPNB1 functions as an oncogene in EOC. In contrast to the apoptosis induced by KPNB1 inhibition (Fig. 3) , KPNB1 overexpression significantly decreased caspase-3/7 activity (Fig. 5D ), in addition to the expression levels of cleaved caspase-3 and BAX proteins (Fig. 5E ). KPNB1 overexpression also decreased p21 and p27 protein levels (Fig. 5E) , as opposed to their increase by KPNB1 inhibition (Fig. 4E) . Collectively, these results indicate that KPNB1 functions as an antiapoptotic and proproliferative oncogene in EOC. To assess the clinical relevance of its oncogenic function, we analyzed the relationship between KPNB1 expression and EOC patient prognosis using a publicly available microarray dataset (GSE 9891) (20) . Patients with higher expression levels of KPNB1 showed earlier recurrence and worse prognosis than those with lower expression levels of KPNB1 (Fig. S7 A and B) , further confirming that KPNB1 acts as an oncogene in human EOC and represents a promising therapeutic target.
KPNB1 Positively Regulates Members of the Anaphase-Promoting
Complex/Cyclosome. KPNB1 functions as a nucleocytoplasmic transporter to import proteins containing nuclear localization signals into the nucleus (21) . We thus decided to perform stable isotope labeling with amino acids in cell culture (SILAC) and mass spectrometric (MS) analysis to identify proteins shuttled by KPNB1 into the nucleus in a high-throughput manner. SKOV3 and OVCAR3 cells were transfected with NC siRNA or KPNB1 siRNA, labeled with light or heavy amino acids, respectively, and analyzed by quantitative MS (Fig. 6A) . Comprehensive analysis revealed that protein levels of multiple anaphase-promoting complex/cyclosome (APC/C) family members decreased in the nucleus of cells treated with KPNB1 siRNA (Fig. 6B) . APC/C is a positive regulator of mitosis and functions as an E3 ubiquitin ligase to mark cell cyclerelated proteins for proteasomal degradation (22) . Loss of APC/C results in cell cycle arrest at metaphase and severe aberrations of the mitotic spindle (23) . To further investigate the relationship between KPNB1 and APC/C protein levels, we analyzed liquid chromatography (LC)-MS data for various other human cancer cell lines (24) . We observed a positive correlation in protein levels between KPNB1 and multiple APC/C family members in several different cancer types (Fig. 6C) , suggesting that regulation of APC/C proteins by KPNB1 may not be unique to EOC. In addition, we found that KPNB1 inhibition significantly decreased cell proliferation/ viability in many other human cancer cell lines including breast, pancreas, and liver (Fig. 6D) , suggesting that KPNB1 could also be a potential therapeutic target for these cancers in addition to EOC.
Ivermectin Exerts a Strong Antitumor Effect On EOC in a KPNB1-Dependent Manner. Next, we searched clinically available drugs that can potentially target KPNB1 and found a recent report that ivermectin, an FDA-approved antiparasitic drug, inhibits importin α/β-mediated nuclear import (25) . In our initial studies, we found that ivermectin treatment suppressed cell proliferation/viability in a dose-dependent manner (Fig. 7A ), indicating that it exerts an antitumor effect on EOC. Similar to KPNB1 inhibition or importazole treatment, ivermectin also induced apoptosis (Fig. 7 B and C) . We also found that ivermectin increased the expression levels of BAX, and cleaved PARP, as well as p21 and p27 (Fig. 7D) . Cell cycle analysis with nocodazole also showed a cell cycle arrest upon ivermectin treatment, similar to what we observed with KPNB1 inhibition ( Fig. 7 E and F) . These findings suggest that ivermectin exerts its antitumor effect through the same mechanisms as KPNB1 inhibition. To provide additional validation, we treated SKOV3 and OVCAR3 cells with ivermectin in the absence of KPNB1. In sharp contrast to the strong antitumor effect we observed for ivermectin in NC siRNA-treated cells, we observed a severely diminished effect for ivermectin in KPNB1 siRNA-treated cells (Fig. 7G and Fig. S8 ), indicating that KPNB1 inhibition is responsible for the antitumor effect of ivermectin.
Ivermectin Synergistically Suppresses EOC Tumor Growth in Combination
with Paclitaxel. Paclitaxel is a drug currently in use for EOC. It is used as a first-line chemotherapy in combination with platinum, or as a second-line therapy for platinum/paclitaxel-refractory cancers (26) . We thus explored the potential of ivermectin combined with paclitaxel for the treatment of EOC. Interestingly, we found that ivermectin synergistically reduced cell proliferation/viability in combination with paclitaxel in human EOC cells (Fig. 7H) , via the induction of apoptosis and cell cycle arrest at the G2/M phase ( Fig.  7 I and J and Fig. S9 ). Lastly, we tested this combination therapy in vivo. Single treatment of ivermectin or paclitaxel reduced tumor growth in nude mice, but, notably, combination treatment of ivermectin and paclitaxel almost completely suppressed tumor growth (Fig. 7K) . These results identify ivermectin and paclitaxel as a promising combinatorial therapy for human EOC.
Discussion
We identified, in this study, several candidate drug targets for EOC using a combination of shRNA and CRISPR/Cas9 library screening. Among these drug targets, we showed that inhibition of one, KPNB1, by ivermectin has promising antitumor effects and synergizes with paclitaxel in the treatment in EOC. While RNAi/ shRNA/CRISPR/Cas9 library screening was originally developed for use in vitro, more recently, these technologies have been used in vivo to mimic a more clinically relevant physiological environment (27) . Several in vivo loss of function screens using RNAi or CRISPR-Cas9 have been reported that identified shRNAs or sgRNAs, which were enriched in tumors, but the targets of these screens are mostly undruggable tumor suppressor genes (27, 28) . In contrast, our screen focused on shRNAs or sgRNAs (CRISPR/ Cas9) that are depleted in tumors and thus potentially represent druggable oncogenes. We also performed multiple screens using the same experimental conditions, to help eliminate background noise. Interestingly, we observed depletion of many more genes in tumors using CRISPR/Cas9 compared with shRNA. We first excluded the possibility that cancer cells containing the CRISPR library were engrafted unsuccessfully, because the tumor size and growth were similar in both screens. We also confirmed that essential genes, identified by previously reported CRISPR screens (29, 30) , were significantly more depleted than nonessential genes in peritoneal tumors in our CRISPR screen [depletion rate; essential genes vs. nonessential genes defined by Blomen et al. (29) , respectively], suggesting that genes were not depleted randomly but by in vivo selective pressure. The shRNA generally induces partial gene knockdown, and the residual activity of the wild-type protein may thus prevent a knockdown phenotype from being observed. This is in contrast to CRISPR/Cas9, where complete gene knockouts are usually produced. This functional difference between RNAi and CRISPR/Cas may be, at least in part, responsible for the different screening output. By analyzing both types' loss-of-function screens, we hoped to provide a more highly reliable list of drug targets for EOC.
Our top-ranked gene, ERBB2, is amplified and overexpressed in many cancers, including breast (31), ovary (31), colon (32), bladder (33), non-small-cell lung (34) , and gastric cancer (35) , and is a poor prognostic factor in certain cancer types (36, 37) . Several HER2 inhibitors, either tyrosine kinase inhibitors or monoclonal antibodies, are already in clinical use and are invaluable drugs in the treatment of breast cancer. Regarding their clinical implications for EOC, several clinical trials using HER2 inhibitors have already been conducted with unsatisfying results (38, 39) , However, the latest phase III clinical trials (pertuzumab in platinum-resistant low human epidermal growth factor receptor 3 messenger ribonucleic acid epithelial ovarian cancer; PENELOPE) for EOC have shown favorable results for pertuzumab combined with gemcitabine and paclitaxel for platinum-resistant EOC with low HER3 mRNA levels (40) . In accordance with these results, SKOV3 has the highest expression levels of HER2, and the fifth-lowest expression levels of HER3, among 52 EOC cell lines registered in the cancer cell line encyclopedia (41) , which might have resulted in the identification of ERBB2 as the most potent drug target in our screen.
KPNB1 was the second-highest-ranked gene identified in our screen. Increased KPNB1 protein levels have been reported in several cancers, including cervical cancer (42), hepatocellular carcinoma (43) , and glioma (44) , suggesting KPNB1's oncogenic potential in these tumor types. In this study, we validated an oncogenic function of KPNB1 in EOC through apoptosis inhibition and cell cycle progression. MS analysis also revealed the positive regulation of several APC/C family members by KPNB1, suggesting that KPNB1 might shuttle these nuclear proteins related to cancer progression. To determine whether these proteins directly interact, we further performed MS of proteins immunoprecipitated (IP-MS) with a KPNB1 antibody. Although IP-MS could identify known partner molecules of KPNB1, such as RAN and RAN-GTP, none of the APC/C members were identified in this assay (Dataset S1). This may be because interaction between APC/C and KPNB1 is not static, or KPNB1 might indirectly affect APC/C protein levels in the nucleus. Nonetheless, positive regulation of APC/C by KPNB1 could still be important for cell cycle control, since APC/C is known to regulate the cell cycle from late G2/M to G1. Specifically, APC/ C cdc20 is required for anaphase onset and mitotic exit, while APC/ C cdh1 is essential for mitotic exit to G1 (45) . Taken together, our findings suggest that KPNB1 might serve as a master regulator of cell cycle by regulating several cell cycle-related proteins, including p21, p27, and APC/C family members.
Ivermectin has a long history of safe treatments for several parasitic infections in humans and mammals (46) . Recently, Wagstaff et al. (25) has also identified ivermectin as a specific inhibitor of importin α/β-mediated nuclear import via high-throughput screening. Indeed, in this study, we discovered a KPNB1-dependent antitumor effect of ivermectin on multiple EOC cell lines. We found that ivermectin induces apoptosis and multiphase cell cycle arrest in EOC cells, accompanied by alterations in several molecules, all of which are consistent with the alterations we observed upon KPNB1 inhibition. The regimen used for the mice in our study was not the same as the one used for parasite treatment in humans. However, Guzzo et al. (47) reported that higher and/or morefrequent doses of ivermectin than currently approved for humans are well tolerated in humans. In addition, none of the mice in this study treated with the effective dosage of ivermectin for in vivo anticancer therapy showed severe adverse event. Therefore, although we need to optimize the regimen in the clinical settings, considering its strong antitumor effect and accumulated safety profile as an antiparasitic drug, our results identify ivermectin as an attractive alternative therapeutic toward EOC patients through drug repositioning. In addition, we found that the combination of ivermectin and paclitaxel produces a stronger antitumor effect on EOC cell lines than either drug alone. Recently, molecular therapies targeting cell cycle, including CDK4/6 inhibitors, have been approved by the FDA (48) . In addition, cell cycle targeted therapy has been studied in a number of clinical trials, in combination with chemotherapeutic agents, to pursue synergistic antitumor effects. Indeed, the latest phase III clinical trials have shown efficacy for combination therapy of CDK4/6 inhibitors and hormone therapy for breast cancer (49) , via overcoming the resistance to prior hormonal therapy. Although the precise molecular mechanism of the synergistic antitumor effect of ivermectin and paclitaxel needs further investigation, both drugs have been in clinical use for several decades, which should facilitate clinical trials assessing the combinatorial effects of these two drugs in EOC patients.
Methods
Cell Culture. SKOV3, OVCAR3, and CAOV3 human liver cancer cell lines, MIA PaCa-2 human pancreatic cancer cell line, MDA-MB231 and MCF-7 human breast cancer cell lines, and HEK-293 cell line were purchased from the American Type Culture Collection. The Huh-7 human liver cancer cell line was purchased from the Japanese Collection of Research Bioresources Cell Bank. These cell lines were cultured in DMEM or RPMI-1640 medium supplemented with 10% FBS and penicillin−streptomycin, except for OVCAR3, which was supplemented with 0.01 mg/mL of bovine insulin, 20% FBS, and penicillin −streptomycin. All cell lines were maintained in a humid incubator (5% CO 2 , 37°C) that was confirmed to be free from pathogens and mycoplasma.
Chemicals and Reagents for Biological Assays. Ivermectin (Selleckchem), importazole (Selleckchem), paclitaxel (Sigma Aldrich), and nocodazole (Sigma Aldrich) were dissolved in DMSO to prepare stock solutions, and were diluted in cell growth medium for assays.
In Vivo Pooled shRNA Library Screen. Decode pooled shRNA druggable library (#RHS6082) was purchased from GE Dharmacon. Female athymic nude mice [Crl:Nu(NCr)-Foxn1nu] were purchased from Charles River Laboratories. SKOV3 cells were lentivirally transduced with the shRNA library containing 42,450 shRNAs targeting 7,490 genes at a multiplicity of infection (MOI) of 0.2, and transduced cells were selected by 1.5 mg/mL puromycin treatment for 7 d. Pellets of transduced cells were stored at −80°C as a reference for sequencing. Five million transduced cells were i.p. injected into female nude mice. Mice were monitored for tumor formation using the general animal health guidelines, and tumors bigger than 10 mm in diameter were collected 7 wk after injection and snap-frozen. The Institutional Animal Care and Use Committee of Houston Methodist Research Institute approved all mouse procedures.
Genomic DNA Sequence. Genomic DNA was extracted from cells and xenograft tumors transduced with the pooled shRNA or CRISPR/Cas library, using the DNeasy Blood and Tissue kit (Qiagen), according to the manufacturer's instructions. For shRNA library, shRNA sequences of extracted gDNA were then amplified using Illumina-adapted Decode Forward and Reverse indexed PCR primers, according to the protocol supplied with the Decode Pooled Lentiviral shRNA screening libraries. To keep the fold representation at 100 for each of the shRNAs, 27.8 μg of gDNA per each sample was used for the PCR. Indexed PCR products were purified using a PCR purification kit (Qiagen). Purified PCR amplicons were multiplexed and sequenced using Decode sequencing primers on an Illumina Hiseq. For CIRSPR/Cas library, sgRNA sequences were first amplified with forward primer AATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCG and reverse primer TCTACTATTCTTTCCCCTGCACTGTTGTGGGCGATGTGCGCTCTG. Then, they were secondarily amplified with forward primer AATGATACGGCGACCACCGA-GATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT(1-8 bp stagger)(8 bp barcode)TCTTGTGGAAAGGACGAAACACCG and reverse primer CAAGCAGAAG-ACGGCATACGAGATGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTCTACTATT-CTTTCCCCTGCACTGT. To keep the fold representation at 100 for each of the sgRNAs, 45 μg of gDNA per sample was used for the PCR. Purified PCR amplicons were multiplexed and sequenced using Illumina sequencing primers on an Illumina Hiseq. We obtained reads per tumor. The read counts for each unique shRNA/ gRNA for a given sample were normalized as previously described (12) . Then, these normalized read counts were converted into the fold change (FC) relative to those of referential cells. For dropout hit identification, we first selected genes targeted by more than or equal to four shRNAs showing an FC of less than 0.1. Genes were then ranked based on average FC of all designed shRNAs targeting each gene. The top 10 genes, which showed average FC of less than 0.2, are listed in Fig. 1C .
Flow Cytometry. SKOV3 cells were transfected with NC siRNA or KPNB1 siRNA, or treated with anticancer drugs or vehicle. Cell cycle analysis was then performed 2 d later. Cells were first labeled with propidium iodinide (Sigma Aldrich), and their cell cycle was analyzed using a BD LSRFortessa cell analyzer (BD Biosciences). In some experiments, the cells were first synchronized by the addition of nocodazole for 24 h, and the cell cycle was then analyzed. Synchronized cells were also analyzed 24 h after the withdrawal of nocodazole. For apoptosis analysis, 2 d later, the cells were trypsinized and washed with PBS. Cell pellets were then diluted with annexin V binding buffer 10× concentrate (BD Biosciences) and incubated with BD phospholipid-binding protein APC Annexin V (BD Biosciences) and propidium iodinide (Sigma Aldrich). The cells were then analyzed using a BD LSRFortessa cell analyzer. Data were analyzed using BD FACSDiva 8.0.1.
In Vivo Xenografts. Proteomic Analysis. SKOV3 and OVCAR3 cells were labeled with heavy isotope, 13 C 6 L-Lysine-2HCl, or light isotope, L-Lysine-2HCl, via Pierce SILAC Protein quantitation kit-RPMI 1640 containing 10% dialyzed FBS (ThermoFisher Scientific). Cells were passaged and expanded for at least 10 doublings, before transfection of KPNB1 siRNA or NC siRNA. For whole-cell extracts, cells were lysed in 1 mL of PBS containing detergent, protease inhibitor (Roche Diagnostics), and phosphatase inhibitor, 72 h after siRNA transfection, followed by sonication and centrifugation. For nuclear cell extracts, cells were lysed in cell lysis buffer with protease inhibitor and homogenized, followed by centrifugation. Nuclei resuspension buffer was then added to the pellets, followed by centrifugation. For the IP-MS experiment, nuclear cell extracts of SKOV3 were obtained as described above and immunoprecipitated by IgG or KPNB1 antibody (Abcam). MS analysis were performed as previously described (24) . Bioinformatic Analysis. To investigate an association between expression of KPNB1 gene and prognosis in EOC patients, we downloaded GSE9891 dataset from Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) (20) . We obtained Affymetrix Human Genome U133 Plus 2.0 array data from 285 ovarian tumor samples, and their patient survival data. We used the data from 194 advanced stage high-grade serious ovarian cancer patients without chemotherapeutic treatment before the sample collection. We performed Kaplan−Meier survival analysis in R 2.15.3 (R Development Core Team 2013) using package "survival."
Statistical Analysis. All data were analyzed with Graphpad Prism 6 (GraphPad Software) and provided as mean ± SEM unless otherwise indicated. Statistical analyses were performed using an unpaired Student's t test, Mann−Whitney U test, or a one-way ANOVA. For multiple comparisons, P value was adjusted by Bonferroni correction of the differences or the differences in the mean values among the groups were examined by Dunnett's multiple comparison test. P < 0.05 was considered statistically significant. For all other information on materials and methods, please see Supporting Information.
